Approval Times Cut For Pharmaceutical Companies

A box of Erlotinib 100mg tablets, also known by its brand name Tarceva, a cancer treatment drug manufactured by Roche Holding AG, sits alongside a blister pack of five tablets in this arranged photograph in London, U.K., on Friday, April 27, 2018. Tarceva, which is relatively unusual among cancer treatments in that it is given by mouth rather than injection, is for the initial treatment of people with EGFR mutation-positive metastatic non-small cell lung cancer. Photographer: Chris Ratcliffe/Bloomberg via Getty Images
A box of Erlotinib 100mg tablets, also known by its brand name Tarceva, a cancer treatment drug manufactured by Roche Holding AG, sits alongside a blister pack of five tablets in this arranged photograph in London, U.K., on Friday, April 27, 2018. Tarceva, which is relatively unusual among cancer treatments in that it is given by mouth rather than injection, is for the initial treatment of people with EGFR mutation-positive metastatic non-small cell lung cancer. Photographer: Chris Ratcliffe/Bloomberg via Getty Images
Approval Times Cut For Pharmaceutical Companies
LICENTIE KOPEN
Hoe mag ik dit beeld gebruiken?
€ 475,00
EUR

GEGEVENS

Beperkingen:
Neem voor gebruik voor alle commerciële of promotiedoeleinden contact op met uw lokale kantoor.For editorial use only. Additional clearance required for commercial or promotional use, contact your local office for assistance. Any commercial or promotional use of Bloomberg content requires Bloomberg's prior written consent.
Credits:
Bloomberg / Contributor
Redactioneel nr.:
954473454
Collectie:
Bloomberg
Gemaakt op:
26 april 2018
Datum van uploaden:
Soort licentie:
Release-informatie:
Geen release. Meer informatie
Bron:
Bloomberg
Naam materiaal:
PHARMACEUTICAL INDUSTRY
Max. bestandsgrootte:
4000 x 2667 px (33,87 x 22,58 cm) - 300 dpi - 2 MB